SCHEMBL17508370

SCHEMBL17508370

Clc1nc(-c2cc3ccccc3c3ccccc23)c2cccnc2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.43
CCR1 P32246 2/20 0.41
CCR8 P51685 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
ALDH1A1 P00352 3/20 0.41
RPS6KA5 O75582 1/20 0.39
CYP3A4 P08684 2/20 0.38
MAPT P10636 2/20 0.38
MAPK1 P28482 2/20 0.38
LMNA P02545 1/20 0.38
APEX1 P27695 1/20 0.38
PMP22 Q01453 1/20 0.38
NISCH Q9Y2I1 1/20 0.38
ACHE P22303 1/20 0.36
IDO1 P14902 2/20 0.36
HPGD P15428 2/20 0.35
HSD17B10 Q99714 2/20 0.35
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.35
ABCG2 Q9UNQ0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17508362 0.84 CCR1 (0.41) CYP11B1CCR1CCR8L3MBTL1ALDH1A1
SCHEMBL15860241 0.83 ALDH1A1 (0.49) CCR1CCR8L3MBTL1ALDH1A1RPS6KA5
SCHEMBL18688232 0.79 CCR1 (0.46) CYP11B1CCR1CCR8L3MBTL1ALDH1A1
SCHEMBL15860269 0.78 HTR2B (0.44) CYP11B1CCR1CCR8L3MBTL1ALDH1A1
SCHEMBL30731308 0.78 KDM4E (0.53) CYP11B1L3MBTL1ALDH1A1MAPTMAPK1
SCHEMBL15860243 0.78 KDM4E (0.53) CYP11B1L3MBTL1ALDH1A1MAPTMAPK1
SCHEMBL4146794 0.78 KDM4E (0.52) L3MBTL1ALDH1A1RPS6KA5MAPTLMNA
SCHEMBL24010021 0.75 IDO1 (0.41) CCR1CCR8L3MBTL1RPS6KA5IDO1
SCHEMBL30160518 0.75 IDO1 (0.41) CCR1CCR8L3MBTL1RPS6KA5IDO1
SCHEMBL20256139 0.75 RPS6KA5 (0.36) ALDH1A1RPS6KA5MAPTLMNANISCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9676767-B2 Indoloacridine-containing derivative, preparation process and use thereof, and organic luminescent device BOE TECHNOLOGY GROUP CO., LTD. (CN) 2017-06-13 US disclosed
US-20160046621-A1 INDOLOACRIDINE-CONTAINING DERIVATIVE, PREPARATION PROCESS AND USE THEREOF, AND ORGANIC LUMINESCENT DEVICE BOE TECHNOLOGY GROUP CO., LTD. (CN) 2016-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160046621-A1 INDOLOACRIDINE-CONTAINING DERIVATIVE, PREPARATION PROCESS AND USE THEREOF, AND ORGANIC LUMINESCENT DEVICE AHR, CDYL, SLC18A1 CYP11B1 2073/4885CCR1 4109/4885CCR8 3753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.